Ignite Creation Date:
2024-05-06 @ 3:25 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04629872
Status:
UNKNOWN
Last Update Posted:
2022-04-13
First Post:
2020-11-11
Brief Title:
Fingolimod in Endovascular Treatment of Ischemic Stroke
Sponsor:
Ning Wang MD PhD
Organization:
First Affiliated Hospital of Fujian Medical University
Study Overview
Official Title:
Combinating Fingolimod With Endovascular Treatment in Acute Ischemic Stroke
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 45 hours of disease onset or in combination with alteplase within 45 hours of disease onset This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None